Severe heart failure after bortezomib treatment in a patient with multiple myeloma: A case report and review of the literature

Acta Haematologica

Volumn 128, Issue 4, 2012, Pages 244-247

  Bockorny, Margarita ^a   Chakravarty, Saneka ^a   Schulman, Peter ^a   Bockorny, Bruno ^a   Bona, Robert ^a  

^a UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

Author keywords

Bortezomib; Multiple myeloma; Severe heart failure

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; GADOLINIUM; ZOLEDRONIC ACID;

ADULT; ANGIOCARDIOGRAPHY; BONE MARROW BIOPSY; BREATHING DISORDER; CARDIOMEGALY; CARDIOVASCULAR MAGNETIC RESONANCE; CASE REPORT; CLINICAL EXAMINATION; DISEASE SEVERITY; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FLOW CYTOMETRY; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE WALL MOTION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERTENSION; IMAGE ENHANCEMENT; LUNG CONGESTION; MEDICAL HISTORY; MITRAL VALVE REGURGITATION; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; ORTHOPNEA; PAROXYSMAL DYSPNEA; PERICARDIAL EFFUSION; PHYSICAL EXAMINATION; PLEURA EFFUSION; PRIORITY JOURNAL; REVIEW; THORAX RADIOGRAPHY; TRANSTHORACIC ECHOCARDIOGRAPHY; TWO DIMENSIONAL ECHOCARDIOGRAPHY;

AMYLOIDOSIS; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; FEMALE; HEART FAILURE; HUMANS; MIDDLE AGED; MULTIPLE MYELOMA; MYOCARDITIS; PROTEASOME INHIBITORS; PYRAZINES;

EID: 84865839725     PISSN: 00015792     EISSN: 14219662     Source Type: Journal    
DOI: 10.1159/000340050     Document Type: Review

References (25)

1. Adams J: The proteasome: A suitable antineoplastic target. Nat Rev Cancer 2004; 4: 349-360. (Pubitemid 38579481)
2. IBC medical policy bulletin: Bortezomib (Velcade -) . Policy: 08.00.73c.
3. Lara PN Jr, Longmate J, Reckamp K, Gitlitz B, Argiris A, Ramaligan S, Belani CP, Mark PC, Lau DH, Koczywas M, Wright JJ, Shepherd FA, Leighl N, Gandara DR: Randomized phase II trial of concurrent versus sequential bortezomib plus docetaxel in advanced non-small-cell lung cancer: A California cancer consortium trial. Clin Lung Cancer 2011; 12: 33-37.
4. Scagliotii GV, Germonpré P, Bosquée L, Vansteenkiste J, Gervais R, Planchard D, Reck M, De Marinis F, Lee JS, Park K, Biesma B, Gans S, Ramlau R, Szczesna A, Makhson A, Manikhas G, Morgan B, Zhu Y, Chan KC, von Pawel J: A randomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer. Lung Cancer 2010; 68: 420-426.
5. Millennium Pharmaceuticals: Velcade (bortezomib) for injection - prescribing information for the United States. 2005.
6. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, San-Miguel JF, Blade J, Boccadoro M, Cavenagh J, Dalton WS, Boral AL, Esseltine DL, Porter JB, Schenkein D, Anderson KC: Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487-2498. (Pubitemid 41007864)
7. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar V, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkein DP, Anderson KC: A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348: 2609-2617. (Pubitemid 36741588)
8. Jagannath S, Barlogie B, Berenson J, Siegel D, Irwin D, Richardson PG, Niesvizky R, Alexanian R, Limetani SA, Alsina M, Adams J, Kauffman M, Esseltine DL, Schenkein DP, Anderson KC: A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004; 127: 165-172. (Pubitemid 39371809)
9. Voortman J, Giaccone G: Severe reversible cardiac failure after bortezomib treatment combined with chemotherapy in a non-small cell lung cancer patient: A case report. BMC Cancer 2006; 6: 129.
10. Hacihanefioglu A, Tarkun P, Gonullu E: Acute severe cardiac failure in a myeloma patient due to proteasome nhibitor bortezomib. Int J Hemat 2008; 88: 219-222.
11. Orciuolo E, Buda G, Cecconi N, Galimberti S, Versari D, Cervetti G, Salvetti A, Petrini M: Unexpected cardiotoxicity in haematologic bortezomib treated patients. Br J Haemat 2007; 138: 396-397.
12. Foley PW, Hamilton MS, Leyva F: Myocardial scarring following chemotherapy for multiple myeloma detected using late gadolinium hyperenhancement cardiovascular magnetic resonance. J Cardiovasc Med (Hagerstown) 2010; 11: 386-388.
13. Takamatsu H, Yamashita T, Kotani T, Sawazaki A, Okumura H, Nakao S: Ischemic heart disease associated with bortezomib treatment combined with dexamethasone in a patient with multiple myeloma. Int J Hematol 2010; 91: 903-906.
14. Dasanu CA: Complete heart block secondary to bortezomib use in multiple myeloma. J Oncol Pharm Pract 2011; 17: 282-284.
15. Adams J: The proteasome: structure, function, and role in the cell. Cancer Treat Rev 2003; 29(suppl 1):3-9. (Pubitemid 36626287)
16. Zolk O, Schenke C, Sarikas A: The ubiquitinproteasome system: focus on the heart. Cardiovasc Res 2006; 70: 410-421.
17. Powell SR: The ubiquitin-proteasome system in cardiac physiology and pathology. Am J Physiol Heart Circ Physiol 2006; 291: 1-19.
18. Bristow MR, Thompson PD, Martin RP, Jason JW, Billingham ME, Harrison DC: Early anthracycline cardiotoxicity. Am J Med 1978; 65: 823-832. (Pubitemid 9078065)
19. Shan K, Lincoff M, Young JB: Anthracycline- induced cardiotoxicity. Ann Intern Med 1996; 125: 47-58.
20. Syed IS, Glockner JF, Feng D, Araoz PA, Martinez MW, Edwards WD, Gertz MA, Dispenzier A, Oh JK, Bellavia D, Tajik AJ, Grogan M: Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis. JACC Cardiovasc Imaging 2010; 3: 155-164.
21. Maceira AM, Joshi J, Prasad SK, Moon JC, Perugini E, Harding I, Sheppard MN, Poole- Wilson PA, Hawkins N, Pennell DJ: Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 2005; 111: 186-193. (Pubitemid 40139730)
22. Abdel-Aty H, Boye P, Zagrosek A, Wassmuth R, Kumar A, Messroghli D, Bock P, Dietz R, Friedrich MG, Schulz-Menger J: Diagnostic performance of cardiovascular magnetic resonance in patients with suspected acute myocarditis: Comparison of different approaches. J Am Coll Cardiol 2005; 45: 1815- 1822. (Pubitemid 40779862)
23. Wu CF, Chuang WP, Li AH, Hsiao CH: Cardiac magnetic resonance imaging in sunitinib malate-related cardiomiopathy: No late gadolinium enhacement. J Chin Med Assoc 2009; 72: 323-327.
24. Fallah-Rad N, Lytwn M, Fang T, Kirkpatrick I, Jassal DS: Delayed contrast enhancement cardiac magnetic resonance imaging in trastuzumab induced cardiomyopathy. J Cardiovasc Magn Reson 2008; 10: 5.
25. Khan ML, Stewart AK: Carfilzomib: A novel second-generation proteasome inhibitor. Future Oncol 2011; 7: 607-612.